Merck Other Stockholder Equity from 2010 to 2024

MRK Stock  USD 130.23  0.68  0.52%   
Merck Other Stockholder Equity yearly trend continues to be quite stable with very little volatility. Other Stockholder Equity may rise above about -12.3 B this year. From the period between 2010 and 2024, Merck, Other Stockholder Equity regression line of its data series had standard deviation of  11,570,603,101 and standard deviation of  11,570,603,101. View All Fundamentals
 
Other Stockholder Equity  
First Reported
1985-12-31
Previous Quarter
-12.9 B
Current Value
-12.9 B
Quarterly Volatility
11.6 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.5 B, as well as many exotic indicators such as Price To Sales Ratio of 4.3, Dividend Yield of 0.0246 or PTB Ratio of 6.91. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.
  
This module can also supplement Merck's financial leverage analysis and stock options assessment as well as various Merck Technical models . Check out the analysis of Merck Correlation against competitors.

Latest Merck's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Merck Company over the last few years. It is Merck's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Merck Other Stockholder Equity Regression Statistics

Arithmetic Mean(3,340,423,333)
Geometric Mean6,553,509,230
Coefficient Of Variation(346.38)
Mean Deviation9,732,608,444
Median(3,892,000,000)
Standard Deviation11,570,603,101
Sample Variance133878856.1T
Range34.1B
R-Value(0.85)
Mean Square Error41147709.8T
R-Squared0.71
Significance0.000072
Slope(2,187,124,464)
Total Sum of Squares1874303985.7T

Merck Other Stockholder Equity History

2024-12.3 B
2023-12.9 B
2022-12.1 B
2021-12.9 B
2020-17.2 B
2019-16.3 B
2018-12.1 B

About Merck Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merck income statement, its balance sheet, and the statement of cash flows. Merck investors use historical funamental indicators, such as Merck's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Merck investors may use each financial statement separately, they are all related. The changes in Merck's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merck's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merck Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merck. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity-12.9 B-12.3 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out the analysis of Merck Correlation against competitors.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
CEOs Directory
Screen CEOs from public companies around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.685
Dividend Share
2.96
Earnings Share
0.89
Revenue Per Share
24.215
Quarterly Revenue Growth
0.089
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.